Bayer Aktiengesellschaft

Henning Sommermeyer

Thomas Glaser

Hans-Georg Heine

Rudolf Schohe-Loop

Bodo Junge

Klaus Urbahns

Reilinde Wittka

Jean-Marie-Viktor De Vry

Wolfgang Dompert

Jean M De Vry

Siegfried Goldmann

Hartmund Wollweber

Jean Marie Viktor De Vry

Egbert Wehinger

Otto Behner

Peter-Rudolf Seidel

Jean-Marie Viktor De Vry

The invention relates to the use of 5-substituted pyridine- and hexahydroquinoline-3-carboxylic acid derivatives, some of which are known, for the production of medicaments, in particular for the treatment of cerebral disorders.

Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system

The present invention relates to the new use of 1,2-bridged 1,4-dihydropyridines which are known in some cases, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 and a have the meaning indicated in the description, processes for their preparation and their use as medicaments, as selective potassium channel modulators, in particular for the treatment of the central nervous system.

Use of 1,2-Bridged 1,4-dihydropyridines as medicaments

The present invention relates to new 2,3-bridged 1,4-dihydropyridines of the general formula (I), ##STR1## in which R, R.sup.1, R.sup.2, D and E have the meaning given in the description, processes for their preparation and their use as medicaments, preferably for treatment of the central nervous system.

2,3-bridged 1,4-dihydropyridines, and their use as medicaments

Triazaspirodecanone-methylchromans are prepared by reacting methylchromans, which are substituted on the methyl group by appropriate leaving groups, with triazaspirodecanones. The substances can be employed for the production of medicaments, in particular for medicaments for the control of disorders of the central nervous system.

Triazaspirodecanone-methylchromans

Use of 1,2-bridged 1,4-dihydropyridines as medicaments

Diseases characterized by disturbances of the serotoninergic system, psychoses and depression are treated by administration of an aminomethyl-chroman of the formula ##STR1##

2-aminomethyl-chromans effective in the treatment of psychoses and

The present invention relates to the use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters, some of which are known, of the general formula (I) ##STR1## in which A and R.sup.1 -R.sup.3 have the meaning given in the description, as medicaments, in particular for treatment of the central nervous system, and new selected active compounds.

Use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters as medicaments

The present invention relates to the new use of 1-alkyl-3,5-diacyl-1,4-dihydropyridines which are known in some cases, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 have the meaning indicated in the description, processes for their preparation and their use as medicaments, as selective potassium channel modulators, in particular for the treatment of the central nervous system.

5-acyl-1,4-dihydropyridines

Use of substituted 6-amino-4H-pyrans

Use of N-substituted phenothiazines

Dioxo-thiopyrano-pyridine-carboxylic acid derivatives and their use as

Azaheterocyclylmethyl-chromans of the formula: ##STR1## in which E represents an azaheterocyclyl group selected from the group consisting of: ##STR2## wherein R.sup.6 represents hydrogen, hydroxyl, halogen or phenyl; and

Azaheterocyclymethyl-chromans

A method of treating psychosis by administering to a patient an azaheterocyclylmethyl-chroman of the formula: ##STR1## in which E represents an azaheterocyclyl group selected from the group consisting of: ##STR2## wherein R.sup.6 represents hydrogen, hydroxyl, halogen or phenyl; and represents an integer 0-8; and the other substituents are as defined herein; or an optically isomeric form thereof or a salt thereof.

Method of treating psychosis using azaheterocyclylmethyl

Azaheterocyclylmethyl-chromans are prepared by reaction of corresponding methylchromans with corresponding azaheterocyclic compounds, optionally with subsequent variation of the substituents. The azaheterocyclylmethyl-chromans can be used as active compounds in medicaments, in particular for the treatment of diseases of the central nervous system.

Method of treating depression using azaheterocyclylmethyl-chromans

The application relates to substituted 4-phenyl-6-amino-nicotinic acid derivatives for therapeutic use, to novel active compounds and to their use as cerebrally active agents. The active compounds are prepared by oxidizing appropriately substituted dihydropyridines according to customary methods.

Growing community of inventors

Koln, Germany

Henning Sommermeyer